# Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

> **NCT04095689** · PHASE2 · TERMINATED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 8 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Anthracycline-refractory TNBC

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Pembrolizumab
- **DRUG:** IL-12 gene therapy

## Key facts

- **NCT ID:** NCT04095689
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-12
- **Primary completion:** 2024-06-03
- **Final completion:** 2024-06-03
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Stopping rules met per protocol, trial will be terminated
- **Last updated:** 2026-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04095689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04095689, "Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04095689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*